Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃ for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
IPO Year: 2015
Exchange: NASDAQ
Website: vikingtherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/29/2025 | $104.00 | Overweight | Cantor Fitzgerald |
| 4/8/2025 | $30.00 | Neutral | Goldman |
| 2/13/2025 | $102.00 | Sector Outperform | Scotiabank |
| 2/7/2025 | $38.00 | Neutral | Citigroup |
| 12/2/2024 | Overweight | Piper Sandler | |
| 11/22/2024 | $109.00 | Buy | B. Riley Securities |
| 11/4/2024 | $90.00 → $102.00 | Buy | H.C. Wainwright |
| 9/11/2024 | $80.00 | Overweight | JP Morgan |
| 6/27/2024 | $105.00 | Overweight | Morgan Stanley |
| 5/16/2024 | $115.00 → $116.00 | Outperform → Strong Buy | Raymond James |
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
SCHEDULE 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
10-Q - Viking Therapeutics, Inc. (0001607678) (Filer)
DEFA14A - Viking Therapeutics, Inc. (0001607678) (Filer)
DEFR14A - Viking Therapeutics, Inc. (0001607678) (Filer)
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
DEFA14A - Viking Therapeutics, Inc. (0001607678) (Filer)
DEF 14A - Viking Therapeutics, Inc. (0001607678) (Filer)
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
4/A - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
SAN DIEGO, May 28, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. Details of the company's participation are as follows: William Blair 45th Annual Growth Stock ConferenceDetails: Viking management will deliver a corporate presentation, and participate in a fireside chat and 1-on-1 meetingsConference Date: June 3-5, 2025Presentation T
Conference call scheduled for 4:30 p.m. ET today Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected 2H25Broad Manufacturing Agreement with CordenPharma to Support Future Commercialization of VK2735Strong Quarter-End Cash Position of $852 MillionSAN DIEGO, April 23, 2025 /PRNewswire/ --Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2025, and provided an update on its clinical pipeline and other corporate
Conference Call Scheduled for Wednesday, April 23 at 4:30 p.m. Eastern Time SAN DIEGO, April 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2025 after the market close on Wednesday, April 23, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on We
13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabo
CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735.CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735.CordenPharma provides fill-finish for the drug candidate's subcutaneous formulation and oral solid dosage manufacturing for its oral peptide formulation.BASEL, Switzerland, March 11, 2025 /PRNewswire/ -- CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in the supply of peptide APIs and peptide-based therapeutic finished dosage drug products, is pleased to announce the sig
Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply and Additional 100 Million Annual Vial/Syringe Supply Provides Annual Capacity of Over 1 Billion Oral Tablets Viking to Make Prepayments Totaling $150 Million Between 2025-2028 SAN DIEGO, March 11, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has signed a broad, multi-year manufacturing agreement with CordenPharma, an
SAN DIEGO, March 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. Details of the company's participation are as follows: Leerink Partners Global Healthcare Conference 2025Details: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: March 10-12, 2025Fireside Chat Timing: 9:20 – 9:50 a.m. Easte
Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity UnderwayStrong Year-End Cash Position of $903 MillionSAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided an update on its clinical pipeline and other corporate developments.
Conference Call Scheduled for Wednesday, February 5 at 4:30 p.m. Eastern Time SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2024 after the market close on Wednesday, February 5, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. E
13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4/A - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
Cantor Fitzgerald initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $104.00
Goldman initiated coverage of Viking Therapeutics with a rating of Neutral and set a new price target of $30.00
Scotiabank initiated coverage of Viking Therapeutics with a rating of Sector Outperform and set a new price target of $102.00
Citigroup initiated coverage of Viking Therapeutics with a rating of Neutral and set a new price target of $38.00
Piper Sandler initiated coverage of Viking Therapeutics with a rating of Overweight
B. Riley Securities initiated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $109.00
H.C. Wainwright reiterated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $102.00 from $90.00 previously
JP Morgan initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $80.00
Morgan Stanley initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $105.00
Raymond James upgraded Viking Therapeutics from Outperform to Strong Buy and set a new price target of $116.00 from $115.00 previously
Conference call scheduled for 4:30 p.m. ET today Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected 2H25Broad Manufacturing Agreement with CordenPharma to Support Future Commercialization of VK2735Strong Quarter-End Cash Position of $852 MillionSAN DIEGO, April 23, 2025 /PRNewswire/ --Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2025, and provided an update on its clinical pipeline and other corporate
Conference Call Scheduled for Wednesday, April 23 at 4:30 p.m. Eastern Time SAN DIEGO, April 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2025 after the market close on Wednesday, April 23, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on We
Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity UnderwayStrong Year-End Cash Position of $903 MillionSAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided an update on its clinical pipeline and other corporate developments.
Conference Call Scheduled for Wednesday, February 5 at 4:30 p.m. Eastern Time SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2024 after the market close on Wednesday, February 5, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. E
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Conference call scheduled for 4:30 p.m. ET today End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis Selected for Oral Presentation at AASLDPositive Phase 1b Results from VK0214 Study in X-ALD Demonstrate Safety, Tolerability and Reductions in Very Long-Chain Fatty Acids and Plasma LipidsStrong Quarter-End Cash Position of $930 MillionSAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrin
Conference Call Scheduled for Wednesday, October 23 at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the third quarter 2024 after the market close on Wednesday, October 23, 2024. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
Conference call scheduled for 4:30 p.m. ET today VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24Oral VK2735 Phase 2 Study in Obesity Expected to Begin 4Q24Positive Biopsy Results From VK2809 Reported in June; End-of-Phase 2 Meeting in NASH/MASH Planned for 4Q24Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected 2H24In Vivo Data From Novel Amylin Agonist Program Reported at ADA in June; IND in Obesity Planned for 2025SAN DIEGO, July 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, tod
Conference Call Scheduled for Wednesday, July 24 at 4:30 p.m. Eastern Time SAN DIEGO, July 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter 2024 after the market close on Wednesday, July 24, 2024. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wedn
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)